Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.47 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.47 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.47 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.47 |
| ▸ | NCF1 | P14598 | 1/20 | 0.45 |
| ▸ | CCR3 | P51677 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21471559 | 0.93 | LMNA (0.47) | LMNAKMT2AMEN1CARM1PRMT6 | |
| SCHEMBL13185171 | 0.83 | HTR2A (0.49) | CARM1PRMT6PRMT3PRMT1PRMT8 | |
| SCHEMBL8302417 | 0.83 | OPRM1 (0.51) | LMNACARM1PRMT6CCR3KDM4E | |
| SCHEMBL23183592 | 0.82 | LMNA (0.50) | LMNACARM1PRMT6 | |
| SCHEMBL13498031 | 0.82 | MAOB (0.47) | LMNAADRA2C | |
| SCHEMBL13632568 | 0.82 | KDM4E (0.50) | KMT2AMEN1CARM1PRMT6PRMT3 | |
| SCHEMBL7446113 | 0.82 | MEN1 (0.49) | KMT2AMEN1ALDH1A1GFER | |
| SCHEMBL8302415 | 0.81 | OPRM1 (0.51) | — | |
| SCHEMBL21443558 | 0.81 | CCR3 (0.45) | CARM1PRMT6PRMT3PRMT1PRMT8 | |
| SCHEMBL578726 | 0.81 | SLC6A2 (0.52) | CARM1PRMT6PRMT3PRMT1PRMT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144844-A1 | SELECTIVE DIHYDROPYRROLOPYRIMIDINE JAK2 INHIBITORS | Shanghai Xunhe Pharmaceutical Technology Co. Ltd. (CN) | 2022-05-12 | — | — | US | disclosed |
| WO-2021017384-A1 | DIHYDRO-PYRROLO-PYRIMIDINE SELECTIVE JAK2 INHIBITOR | 上海勋和医药科技有限公司 | 2021-02-04 | — | — | WO | disclosed |
| US-20180125855-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2018-05-10 | — | — | US | disclosed |
| US-9849139-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170196881-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2017-07-13 | — | — | US | disclosed |
| US-20170050936-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2017-02-23 | — | — | US | disclosed |
| US-9550770-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150175601-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-06-25 | — | — | US | disclosed |
| EP-1436291-B1 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | AVENTIS PHARMA SA (FR) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170196881-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | LMNA 1977/4885KMT2A 830/4885MEN1 2593/4885 |
| US-20150175601-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | LMNA 1523/4885KMT2A 797/4885MEN1 440/4885 |
| US-20180125855-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | LMNA 1977/4885KMT2A 830/4885MEN1 2593/4885 |
| US-20220144844-A1 | SELECTIVE DIHYDROPYRROLOPYRIMIDINE JAK2 INHIBITORS | JAK2, JAK1, JAK3 | LMNA 4860/4885KMT2A 619/4885MEN1 4068/4885 |
| US-20170050936-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CDK2, MAP3K6, MAP3K2 | LMNA 2760/4885KMT2A 1677/4885MEN1 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.